Peptide Sciences Shut Down: What Happened and Where to Go Now

What happened to Peptide Sciences?

If you've tried to visit PeptideSciences.com recently, you already know the answer: the site is gone. The largest and most well-known grey-market peptide vendor in the United States shut down in early 2026 following a wave of FDA enforcement actions that have fundamentally reshaped access to research peptides in this country.

For the tens of thousands of people who are still searching for “Peptide Sciences,” this shutdown was not just an inconvenience. It was the end of the primary supply chain they relied on for compounds like BPC-157, TB-500, CJC-1295/Ipamorelin, and dozens of other peptides used for recovery, cognition, metabolic optimization, and growth hormone support.

Here is the timeline of what happened, why it happened, and what comes next.

The timeline

• September 2023:Under its longstanding interim policy on bulk drug substances nominated for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, the FDA moves 19 peptide substances into Category 2. The interim policy sorts nominated substances into Category 1 (no significant safety risk identified; compounding permitted under enforcement discretion), Category 2 (significant safety risk identified; not eligible for compounding while under review), and Category 3 (insufficient information to evaluate). Placing these peptides in Category 2 effectively froze legal compounding for those substances. (This category framework comes from FDA's interim 503A guidance and its Pharmacy Compounding Advisory Committee evaluations—not from a 503B “final rule.”)
• June–September 2025:FDA enforcement intensifies against grey-market peptide vendors operating under the “research chemical” label. Multiple vendors receive warning letters. The FDA signals that it considers these sales to be de facto distribution of unapproved new drugs intended for human use.
• October 2025: Amino Asylum, one of the largest grey-market vendors alongside Peptide Sciences, reportedly becomes a target of federal enforcement action according to community and industry reports, and its website goes offline within days. Several smaller vendors preemptively close their storefronts.
• November 2025 – January 2026:A cascade of closures follows. Multiple vendors shutter operations between late 2025 and early 2026. Some announce “temporary pauses.” Others disappear without notice. Peptide Sciences is among the last to go dark.
• Early 2026:Peptide Sciences winds down. According to industry and community reports, the company posted a shutdown notice and stopped accepting orders on March 6, 2026; customer-support channels subsequently went silent and the website is now offline. (This account rests on industry and community reporting rather than a primary regulatory filing—see references.)
• Early 2026:Reporting and industry advocacy emerge—some of it attributed to public statements by HHS officials—suggesting that a number of the Category 2 peptides could be reclassified to Category 1, which would make them eligible for legal compounding again. No formal FDA rule has been published in the Federal Register, so the affected peptides remain Category 2 and restricted.

The net effect: the grey-market infrastructure that supplied peptides to hundreds of thousands of Americans is gone. Some of it was shut down by the FDA. Some of it collapsed on its own. And the regulatory landscape is simultaneously tightening enforcement on unregulated sellers while expanding legal access through licensed compounding pharmacies.

Why did peptide vendors shut down?

The grey-market peptide industry operated for years in a legal grey zone that was never truly grey—it was simply unenforced. Understanding why the FDA moved when it did requires looking at three converging factors: regulatory reclassification, safety concerns, and political pressure.

The “research chemical” fiction collapsed

Companies like Peptide Sciences, Amino Asylum, and dozens of smaller vendors sold peptides labeled “for research purposes only” or “not for human consumption.” This labeling was a legal fig leaf. Everyone involved—vendors, customers, and regulators—understood that the overwhelming majority of these peptides were being purchased for self-injection by individuals managing their own health protocols.

The vendors provided reconstitution instructions. Customer forums discussed dosing protocols openly. Payment was processed through standard merchant accounts. The entire ecosystem was built around personal use, with the “research” label serving as a liability shield that the FDA ultimately decided to pierce.

In enforcement actions throughout 2025, the FDA made clear that it views intent and actual use as more relevant than labeling. When a company sells a reconstitution kit alongside a peptide vial to an individual consumer, the “research only” defense does not hold.

Category 2 restrictions tightened the legal window

The FDA's September 2023 action under its interim 503A bulk drug substances policy placed 19 peptides into Category 2, a designation that prevents them from being compounded by licensed 503A pharmacies under enforcement discretion while the FDA evaluates their safety profiles. The Category 2 list included some of the most widely used compounds in the optimization community:

• AOD-9604
• BPC-157
• Cathelicidin (LL-37)
• CJC-1295
• Dihexa
• DSIP (Delta Sleep-Inducing Peptide / Emideltide)
• Epitalon (Epithalon)
• GHK-Cu (injectable route)
• Ibutamoren (MK-677)
• Ipamorelin
• Kisspeptin-10
• KPV
• Melanotan II
• Mechano Growth Factor, pegylated (PEG-MGF)
• MOTS-c
• Selank
• Semax
• Thymosin Alpha-1
• Thymosin Beta-4 fragment (LKKTETQ; related to TB-500)

Note that FDA-approved products are not on this Category 2 list. Tesamorelin (approved as Egrifta) and bremelanotide/PT-141 (approved as Vyleesi) are FDA-approved drugs, and sermorelin is handled as a compounded prescription product rather than a Category 2 substance—so none of those three appear among the restricted peptides above.

With licensed pharmacies unable to compound these substances, the grey market became the only source. This created a perverse dynamic: the FDA's own restrictions pushed more consumers toward unregulated vendors, which in turn gave the FDA stronger justification for enforcement. The agency argued—with some merit—that the grey market was a public health risk precisely because these compounds lacked the quality controls that licensed pharmacies provide.

Quality and safety concerns were real

This is the part that is uncomfortable for the peptide community to acknowledge, but it matters: the grey market had genuine quality problems. Some independent third-party analyses have reported that a substantial share of grey-market peptide samples were mislabeled, underdosed, or contaminated—in some cases significantly overdosed or underdosed relative to what was on the label.

Grey-market peptides can also carry contamination risks. Independent testing and third-party analyses have reported samples containing bacterial endotoxins, compounds that did not match the label at all, or heavy metals and other manufacturing byproducts. Because these products are made outside cGMP controls, there is no systematic testing to rule such contamination in or out.

This is not to say that all grey-market peptides were dangerous. Many users ran their own third-party tests and sourced from vendors with relatively consistent quality. Peptide Sciences, in particular, had a better reputation than most for providing Certificates of Analysis. But “better than most” in an unregulated market is a low bar. Without mandatory cGMP (current Good Manufacturing Practice) compliance, batch-to-batch consistency was never guaranteed.

Some independent third-party analyses have reported that a substantial share of grey-market peptide samples were mislabeled, underdosed, or contaminated. This is not a fringe quality issue—it points to a systemic weakness of an unregulated supply chain.

The political calculus shifted

The FDA's enforcement posture did not change in a vacuum. Two dynamics drove the timing. First, the GLP-1 agonist market (semaglutide, tirzepatide) generated massive pharmaceutical industry revenue, and grey-market compounders and vendors were cutting into that revenue by offering cheaper alternatives. Pharmaceutical lobbying for enforcement was well-documented throughout 2024 and 2025.

Second, the incoming administration under President Trump appointed Robert F. Kennedy Jr. as HHS Secretary, and RFK's public statements favored expanding access to peptides through legitimate channels rather than allowing unregulated markets to continue. The enforcement actions against grey-market vendors can be understood partly as clearing the field before reopening legal access through compounding pharmacies.

Check your protocol status

If you were sourcing peptides from Peptide Sciences, Amino Asylum, or another grey-market vendor, the first question you need to answer is whether your specific compound is currently available through legal channels—and if not, what its current regulatory status is. Use the tool below to check the current regulatory status of your protocol.

The proposed reclassification: what it would mean

Through 2025 and 2026 there has been reporting and industry advocacy—some of it attributed to public statements by HHS officials—suggesting that a number of the peptides placed in Category 2 could be moved back to Category 1, which would restore their eligibility for legal compounding by licensed 503A and 503B pharmacies. This would be a significant development if it were enacted, but as of this writing it has not been: no formal FDA rule has been published, and the peptides in question remain Category 2 and restricted.

Because nothing has been finalized, the discussion below describes what a reclassification would mean if it happens—not a change that has already taken effect. The regulatory status of peptides can change; verify current FDA status before acting.

What a reclassification would mean practically

Category 1 status means that a peptide can be legally compounded by a licensed pharmacy when prescribed by a physician for an individual patient. This is the standard pathway for compounded medications in the United States. It requires:

• A valid prescription from a licensed physician
• Compounding by a 503A (patient-specific) or 503B (outsourcing facility) pharmacy
• Compliance with USP standards and cGMP requirements
• Batch-specific testing and Certificates of Analysis

For the estimated hundreds of thousands of Americans who were using Category 2 peptides, a reclassification—if it were finalized—would mean a return to legal, quality-controlled access. It would still require a physician to prescribe the compound and a licensed pharmacy to source it—but both of those requirements existed before the grey market emerged, and the infrastructure to support them is already in place. Until any such change is published, these peptides remain restricted.

Which peptides have been discussed for reclassification

Reporting and public commentary have referenced the majority of the Category 2 compounds. No specific list has been published in the Federal Register at the time of this writing, but public statements and reporting have named the following peptides as candidates that could move to Category 1 if a reclassification is enacted:

• BPC-157
• TB-500 (Thymosin Beta-4 fragment)
• CJC-1295
• Ipamorelin
• GHK-Cu
• Selank
• Semax
• KPV
• Epitalon
• DSIP
• MOTS-c
• AOD-9604

Reporting suggests the remaining compounds would likely stay in Category 2 or potentially move to Category 3 (ineligible for compounding), likely due to insufficient safety data or overlap with existing FDA-approved products—though, as with the rest, none of this is settled.

What has not happened yet

It is important to understand what the reported reclassification is and is not. As of July 2026:

• No formal FDA rule has been published.A reclassification has been reported and discussed publicly, but nothing has appeared in the Federal Register as a final rule. Until it does, the legal status of Category 2 peptides has not changed—they remain not FDA-approved and ineligible for legal compounding.
• Compounding pharmacies are in a holding pattern. Licensed pharmacies cannot legally compound Category 2 substances today and are waiting to see whether a formal rule is published. Reports that some are accepting advance prescriptions do not change the fact that no pharmacy can lawfully compound these peptides at present.
• Enforcement against grey-market vendors has not paused. The FDA continues to pursue enforcement actions against unlicensed sellers regardless of any discussion of reclassification. A reclassification, if it happened, would expand legal access through proper channels; it would not retroactively legitimize grey-market operations.

As of this update (July 2026) no formal rule had appeared in the Federal Register, so whether—and when—compounding eligibility might be restored is uncertain, and it may not happen at all—check the Federal Register for the current status. Some 503B outsourcing facilities have reportedly said they are prepared to resume production if and when a formal publication takes effect.

Where to get legitimate peptides in 2026

The grey-market shutdown does not mean peptides are unavailable. It means the access pathway has changed. For many compounds—including GLP-1 agonists like semaglutide and tirzepatide, as well as several growth hormone secretagogues and healing peptides—legitimate, physician-supervised access is available right now. Category 2 compounds remain restricted and are not FDA-approved; legal access would resume only if and when a reclassification is finalized, which has not happened and has no confirmed timeline. For a complete breakdown of what is and isn't legally available, see our complete guide to peptide legality in 2026.

If you're looking for physician-supervised clinics that prescribe peptides and hormones, we've reviewed the major providers in our best online TRT and optimization clinics comparison. For a broader understanding of what peptide therapy involves, start with our complete peptide therapy guide.

Here are your current options, ranked by quality of care and regulatory compliance.

Physician-supervised telehealth clinics

Telehealth clinics that specialize in hormone optimization and peptide therapy offer the most accessible path to legitimate peptide access. These clinics provide physician consultations, lab work interpretation, and ongoing protocol management—and they source compounds exclusively from licensed compounding pharmacies.

The leading clinics in this space include:

• Hone Health: One of the larger telehealth platforms for hormone optimization. Offers testosterone replacement therapy, peptide protocols, and metabolic health programs. Physician consultations are conducted via video. Lab work is coordinated through national lab networks. Pricing is transparent and typically includes both the consultation and the medication.
• Marek Health: Founded by an optimization-focused physician and popular in the biohacking community. Known for more aggressive and individualized protocols compared to some of the more conservative clinics. Offers a wide range of peptides in addition to standard hormone replacement therapy. Strong emphasis on bloodwork-driven protocol adjustments.
• Defy Medical: One of the longest-running telehealth clinics in the hormone optimization space. Based in Tampa, Florida, and operating nationwide via telemedicine. Conservative but thorough approach to protocol management. Extensive experience with complex multi-compound protocols. Often recommended for patients who want a more traditional clinical relationship.

These clinics are not identical. They differ in pricing, physician accessibility, protocol aggressiveness, and the range of compounds they prescribe. But they share one critical characteristic: they source exclusively from licensed pharmacies, and every prescription is written and monitored by a licensed physician.

Compounding pharmacies (503A and 503B)

If you already have a relationship with a prescribing physician—an endocrinologist, a functional medicine doctor, or an anti-aging specialist—you can have peptide prescriptions filled directly at a licensed compounding pharmacy.

There are two types of compounding pharmacies relevant to peptide access:

• 503A pharmacies compound medications for individual patients based on a specific prescription. They are state-licensed and inspected, and they must comply with USP 797 and 800 standards for sterile compounding. Your local compounding pharmacy may be a 503A facility.
• 503B outsourcing facilities are FDA-registered and inspected facilities that can compound larger batches without patient-specific prescriptions. They operate under stricter cGMP requirements and provide batch-specific Certificates of Analysis. Major 503B facilities that compound peptides include Empower Pharmacy, Hallandale Pharmacy, and Olympia Pharmaceuticals.

503B facilities generally offer lower per-unit costs because they produce in larger batches, and they provide more rigorous testing documentation. If your physician is willing to prescribe peptides, a 503B pharmacy is typically the best combination of quality assurance and affordability.

Important: you need a prescription

All legitimate peptide access in 2026 requires a physician's prescription. This is not a new requirement—it has always been the legal standard for injectable peptides intended for human use. The grey market circumvented this requirement by labeling products as “research chemicals,” but that pathway is closed.

If you do not currently have a prescribing physician, the telehealth clinics listed above are the fastest path to establishing one. Most can schedule an initial consultation within one to two weeks, and many can coordinate lab work in advance so that your first appointment is actionable rather than purely diagnostic.

What about Nuletic?

We are building Nuletic as the platform we wished existed when we started our own optimization protocols. Physician-supervised peptide and hormone therapy, AI-powered protocol management, pharmaceutical-grade sourcing from licensed 503B pharmacies, and transparent lab tracking. We are not yet live, but you can join the waitlist to get notified when we launch.

What to avoid

The shutdown of Peptide Sciences and other major vendors has not eliminated the grey market entirely. New vendors have emerged, some operating from overseas, others attempting to replicate the “research chemical” model domestically. These vendors are not safe alternatives. Here is what to avoid and why.

Grey-market vendors still operating

Several vendors continue to sell peptides online using the same “research use only” labeling that Peptide Sciences used. These vendors are operating in direct violation of FDA guidance, and their continued operation is likely temporary. The FDA has demonstrated that it is actively pursuing enforcement, and purchasing from these vendors carries both legal and health risks.

Do not interpret a vendor's continued operation as evidence that it is legitimate. The FDA enforcement process takes time—warning letters, investigations, and seizure actions do not happen overnight. A vendor that is currently online may already be under investigation.

Overseas sources

Chinese and other overseas peptide manufacturers have always been part of the supply chain—many grey-market vendors sourced their raw materials internationally and performed finishing and lyophilization domestically. With domestic vendors shutting down, some consumers are attempting to order directly from overseas manufacturers.

This is the highest-risk option available. Overseas manufacturers selling directly to consumers are not subject to any US regulatory oversight. Quality testing, if it exists at all, is conducted by the manufacturer itself with no independent verification. Customs seizure is common. And the compounds you receive may bear no meaningful relationship to what is described on the label.

“Research use only” products

Any vendor selling injectable peptides to individual consumers with a “research use only” label is selling an unapproved drug. Full stop. The FDA has made its position on this unambiguous. The label does not create a legal safe harbor for the vendor, and it does not protect you as the consumer.

The contamination risk is real

The quality and purity of grey-market peptides is a serious concern that has been raised repeatedly. When you purchase a peptide from an unregulated vendor, there is a real risk that what you are injecting does not match what you think you are injecting.

This is not a theoretical risk. Incorrect dosing in peptides can have real consequences. Overdosed growth hormone secretagogues can cause water retention, carpal tunnel symptoms, and blood sugar dysregulation. Underdosed compounds are therapeutically useless, meaning you are injecting a substance with no benefit while still assuming the risks of injection (infection, immune response, injection site reactions).

Contaminated compounds introduce risks that are even more serious: bacterial endotoxins can cause fever, inflammatory responses, and in severe cases sepsis. Heavy metal contamination from improper manufacturing can accumulate over time with chronic use.

If you are injecting a compound into your body, you deserve pharmaceutical-grade quality assurance. That is not an opinion—it is a minimum standard of care that the grey market was structurally unable to provide.

Social media “sources”

In the wake of the vendor shutdowns, peptide sourcing discussions have migrated to private Telegram groups, Reddit communities, and social media direct messages. Individuals and small operations are offering to sell or broker peptides through these channels. These sources have even less accountability than the established grey-market vendors did. There is no quality testing, no recourse if the product is contaminated or fake, and no way to verify what you are receiving.

Do not source peptides through social media, messaging apps, or anonymous online communities. The risks are not worth the cost savings.

The bottom line

The grey-market era of peptide access in the United States is over. Peptide Sciences, Amino Asylum, and the ecosystem of unregulated vendors that served hundreds of thousands of Americans have been shut down by FDA enforcement, and they are not coming back.

This is not entirely bad news. The grey market existed in part because legitimate access was restricted. Reporting and advocacy suggest that some in government may favor loosening those restrictions, and if a number of peptides were returned to Category 1 compounding status, that would restore legal access through channels that are genuinely safer than what the grey market provided. Whether that happens, and when, is not yet settled.

In the interim, legitimate options exist. GLP-1 agonists like semaglutide and tirzepatide are legally compoundable now. Several growth hormone secretagogues and healing peptides have been discussed as candidates for reclassification, but as of this update (July 2026) they remain restricted and any timeline is uncertain—check the Federal Register for the current status. And physician-supervised telehealth clinics can provide access, monitoring, and protocol management that the grey market never offered.

If you were a Peptide Sciences customer, the path forward is clear:

• Check the status of your specific compounds using the protocol status checker above.
• Establish a relationship with a prescribing physician through a telehealth clinic like Hone Health, Marek Health, or Defy Medical.
• Source exclusively from licensed compounding pharmacies—503A for patient-specific prescriptions, 503B for batch-produced compounds with full testing documentation.
• Do not return to the grey market. The risks were always higher than the community acknowledged. With legitimate access expanding, there is no reason to take those risks now.

At Nuletic, we are building the platform that makes this entire process seamless: physician-supervised protocols, pharmaceutical-grade sourcing, AI-powered optimization, and full transparency from lab work to compound sourcing. We believe your biology deserves the same rigor you would apply to managing your wealth.

Join our waitlist to get early access when we launch.

Frequently asked questions

Is Peptide Sciences coming back?

No. Peptide Sciences shut down in early 2026 following a wave of FDA enforcement actions against grey-market peptide vendors. The site is fully offline, and the regulatory environment that allowed it to operate under a "research chemical" label has fundamentally changed. The FDA has made clear that selling injectable peptides to individual consumers under research-only labels constitutes distribution of unapproved drugs. Peptide Sciences and similar vendors are not expected to return.

Are peptides still legal in 2026?

Yes, many peptides are legal to use with a valid prescription from a licensed physician. What changed is the access pathway. Grey-market vendors selling peptides as "research chemicals" have been shut down, but legitimate access through physician-supervised telehealth clinics and licensed compounding pharmacies remains fully legal. There has also been reporting and industry advocacy that some of the Category 2 peptides could be reclassified to Category 1, which would restore their eligibility for legal compounding—but no formal FDA rule has been published, those peptides remain Category 2 and restricted for now, and the regulatory status of peptides can change, so verify current FDA status before acting.

Where can I buy peptides legally in 2026?

The two legitimate options are physician-supervised telehealth clinics (like Hone Health, Marek Health, or Defy Medical) that prescribe peptides and source them from licensed pharmacies, or working directly with a 503A or 503B compounding pharmacy if you already have a prescribing physician. Both routes require a valid prescription. Any vendor selling injectable peptides without requiring a prescription is operating illegally and should be avoided.

Is it safe to buy peptides online?

It is safe to obtain peptides through licensed telehealth clinics that use 503A or 503B compounding pharmacies for sourcing. These pharmacies operate under strict quality controls including cGMP compliance, batch testing, and FDA oversight. It is not safe to buy peptides from grey-market vendors, overseas manufacturers, social media sellers, or private Telegram groups. Some independent third-party analyses have reported that a substantial share of grey-market peptide samples were mislabeled, underdosed, or contaminated.

What happened to grey-market peptide vendors?

The grey-market peptide vendor ecosystem collapsed between mid-2025 and early 2026. FDA enforcement reportedly intensified with warning letters and enforcement actions; according to community and industry reports, Amino Asylum became a target of federal enforcement action in October 2025 and its website went offline within days. Multiple vendors shut down between late 2025 and early 2026. The FDA pierced the "research chemical" legal defense by demonstrating that these vendors were selling products clearly intended for human use. The remaining grey-market vendors are likely operating temporarily and face ongoing enforcement risk.